TP-122A
Phase 2Biologic
TP-122A is one of 10 biologic programs targeting Ventilator-Associated Pneumonia. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Ventilator-Associated Pneumonia
#DrugCompanyPhaseTrials
1Doribax
ShionogiApproved
Merrem
BB. Braun Medical Inc.
Approved
Amikin
IInsmed Incorporated
Approved
Vancocin
HHikma Pharmaceuticals LLC
Approved
Bactrim
UUniversity of California, San Francisco
Phase 3
Peridex
DDexcel Pharma Technologies Ltd.
Preclinical
Antibiotic
PfizerPreclinical
TP-122A
UUnknown Sponsor
Phase 2
Bacteriophage
AAdaptive Phage Therapeutics, Inc.
Preclinical
Beta Lactam Antibiotics
OOregon Health and Science University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TP-122A. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- UUnknown Sponsor